Recent Updates
Recently added Catalysts

Atenolol Zeneca

Phase 1

Angina | Small molecule | Cardiovascular |Novartis AG|Last Updated: Mar 28, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment28

FDA Designations

No designations recorded

Clinical trial landscape

Atenolol Zeneca · 1 trial · 2 indications

Phase 1 1
NCT00946725To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mgAngina
COMPLETED28 Analytics
PHASE1COMPLETED
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
Angina
NCT0094672528
Unlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence based on AUC and Cmax
20 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALAtenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
2ACTIVE_COMPARATORAtenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Interventions

NameTypeDescription
Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)DRUG -
Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexMALE
Healthy VolunteersYes

Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.

Unlock Eligibility Criteria

Competitive Landscape -Angina 3 trials

CompanyTickerTrialsLead PhaseDrugs
Abbott LaboratoriesABT2N/AUndisclosed
Unlock Competitive Intelligence